Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with a significant unmet medical need, including spinal cord injury and glaucoma.

Axerion was established in New Haven to develop and commercialize intellectual property licensed from Yale University based on work done in Dr. Stephen Strittmatter’s laboratory. Axerion’s proprietary technology platforms include Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.